GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (FRA:V9Z) » Definitions » Short-Term Debt

Aceragen (FRA:V9Z) Short-Term Debt : €0.00 Mil (As of Mar. 2023)


View and export this data going back to . Start your Free Trial

What is Aceragen Short-Term Debt?

Aceragen's Short-Term Debt for the quarter that ended in Mar. 2023 was €0.00 Mil.


Aceragen Short-Term Debt Historical Data

The historical data trend for Aceragen's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen Short-Term Debt Chart

Aceragen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aceragen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aceragen Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Aceragen Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Aceragen's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Aceragen (FRA:V9Z) Business Description

Traded in Other Exchanges
N/A
Address
505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.

Aceragen (FRA:V9Z) Headlines

No Headlines